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Abstract
Background—The underpinnings of the migraine-stroke association remain uncertain, but 
endothelial activation is a potential mechanism. We evaluated the association of migraine and 
vascular disease biomarkers in a community-based population.
Methods—Participants (300 women, 117 men) were recruited as a part of the Dutch CAMERA 1 
(Cerebral Abnormalities in Migraine, an Epidemiologic Risk Analysis) study. Participants were: 
ages 30–60 (mean 48) years, 155 migraine with aura (MA), 128 migraine without aura (MO), and 
134 controls with no severe headaches. Plasma concentrations of fibrinogen, Factor II, D-dimer, 
high sensitivity C-reactive protein (hs-CRP), and von Willebrand factor antigen were compared 
between groups, also stratifying by sex.
Results—Fibrinogen and hs-CRP were elevated in migraineurs compared to controls. In logistic 
regression analyses, MO and MA had increased likelihood of elevated fibrinogen, MA had 
increased likelihood of elevated Factor II and hs-CRP. Fibrinogen and Factor II were associated 
with MA in women but not men. In the migraine subgroup, total number of years of aura, but not 
headache, predicted elevated hs-CRP, and average number of aura, but not headache, attacks 
predicted all biomarkers but Factor II.
Conclusions—Elevated vascular biomarkers were associated with migraine, particularly MA, as 
well as with years of aura and number of aura attacks.
Corresponding author: Gretchen E. Tietjen, MD, University of Toledo Medical Center, Toledo, OH-43614, USA, 
gretchen.tietjen@utoledo.edu; Phone: (419) 383-6187. 
Conflicts of interest:
GET has received grants from GlaxoSmithKline for research endeavors related to biomarkers.
JK has received research funding from Merck Neuroscience Research Laboratories.
HK has received consultancy or industry support from St. Jude Medical, Coherex, Allergan, Merck, Pfizer, GlaxoSmithKline.
GMT reports grants and consultancy/industry support from Menarini, and independent support from NWO and the Dutch Heart 
Foundation.
MF reports grants and consultancy or industry support from Medtronic and independent support from NWO, ZonMW, the National 
Institutes of Health (NIH), the EC, and the Dutch Heart Foundation.
MB has nothing to disclose. NH has nothing to disclose. IP-M has nothing to disclose. MK has nothing to disclose. LL has nothing to 
disclose.
HHS Public Access
Author manuscript
Cephalalgia. Author manuscript; available in PMC 2019 March 01.
Published in final edited form as:
Cephalalgia. 2018 March ; 38(3): 511–518. doi:10.1177/0333102417698936.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Keywords
Migraine; Aura; Headache; Biomarker; Vascular Disease; Inflammation; Stroke; Endothelial 
Activation
Introduction
Migraine is associated with stroke, particularly migraine with aura (1). The migraine 
populations at highest stroke risk includes women, those with high attack frequency, and 
long duration since migraine onset (1,2). Additional factors strengthening the migraine-
stroke relationship include the absence of many of the conventional cardiovascular risk 
factors for atherosclerotic disease (3). In the context of these epidemiological findings, the 
mechanisms to account for the migraine-stroke association have been of considerable 
interest. There is likely a link to an increased (e.g. genetic) propensity to develop cortical 
spreading depression (the electrophysiological correlate of migraine aura), as reported in 
FHM1-mice (4). Further, numerous studies suggested that there might be increased 
endothelial activation in migraine, characterized by a pro-coagulatory and pro-inflammatory 
milieu, but results were variable (5). A clinic-based case-control study of premenopausal 
women reported a robust relationship between biomarkers of oxidative stress, coagulation, 
and inflammation (6) in interictal ICHD 2-defined migraine (7). The migraine-biomarker 
association was influenced by migraine frequency and subtype, being stronger for migraine 
with aura (MA) than for migraine without aura (MO). To date, most of the studies on 
biomarkers in migraine have been limited by the size, age, sex of the populations, or by the 
methods of migraine ascertainment.
Our objective in this study was to overcome such limitations, and to determine, within a 
well-characterized community-based population of men and women across the spectrum of 
adulthood, whether plasma biomarkers related to endothelial activation and vascular disease 
are associated with migraine. To this end, we have evaluated biomarkers from participants in 
the Dutch CAMERA 1 (Cerebral Abnormalities in Migraine, an Epidemiologic Risk 
Analysis) study (8). In this population we were able to examine the influence of the stroke-
associated clinical phenotype (including MA, female sex, and long duration and high attack 
frequency of aura and of headache) on the relationship of vascular disease biomarkers and 
migraine.
Methods
Participants and Sample Selection
The Dutch general population-based Genetic Epidemiology of Migraine (GEM) and its 
substudy, the CAMERA 1 Study have been described previously (8). In brief, 863 persons 
with migraine, diagnosed according to the ICHD 2 criteria (7), and 5628 controls were 
identified in the GEM study (9). Controls were people who indicated that they had no severe 
headaches that interfered with their daily activities. This excluded people with chronic daily 
headache and cluster headache, but people with possible mild migraine attacks or episodic 
tension-type headache may have been included. From those between the ages of 30 to 60 
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years, 134 MO, 161 MA, and 140 controls, who were frequency matched by sex, five-year 
age strata, and place of residence, were randomly selected for the MRI and vascular 
biomarker study. Cases and controls did not differ by age, sex, and cardiovascular risk 
factors (including low education, body mass index [BMI], hypertension, cholesterol, 
diabetes, smoking, and alcohol use). The CAMERA 1 protocol included a structured 
telephone interview and a clinic visit for a brain MRI, blood draw, and a standard physical 
and neurological examination (8). To help the participants estimate headache and aura attack 
frequency, the interview was structured to allow persons to recount their history of migraine 
using their own benchmarks for when a different pattern started and stopped. In addition to 
reported age at first and last migraine and aura attack, these data were used to calculate a 
weighted average of the number of attacks per month. All participants gave written informed 
consent and participated without any financial reimbursement. The study protocol was 
approved by the Leiden University Medical Center, Netherlands ethics committee, and 
exempt from the University of Toledo, USA Institutional Review Board.
Measurement of Confounders and Covariates
Sociodemographic and medical characteristics were assessed by interview. Education was 
categorized into low (primary school or lower vocational education) and high. Smoking 
history was defined as never, former, and current and, for ever smokers, pack-years of 
exposure. The average alcohol intake in the past year was based on responses to questions on 
frequency and quantity of drinks per occasion and categorized into none, moderate (1–3 
drinks per day), and high (≥3 drinks per day). Women reported the number of years they 
used oral contraceptives (OC). Measured weight and height were used to calculate body 
mass index (BMI: weight in kilograms divided by the square of height in meters). Blood 
pressure (BP) was the mean of 3 measurements obtained at 1- minute intervals in the upper 
arm with an electronic oscillometric BP monitor. Hypertension was defined as a systolic BP 
of 160 mmHg and higher or a diastolic BP of 95 mmHg and higher or current use of 
antihypertensive drugs. A measure of total cholesterol was available from the baseline GEM 
examination (8).
Laboratory Testing
The samples were collected ≥ 3 days after and >3 day before a migraine attack during 1999 
and 2000. Samples were taken in a non-fasting state from an ante-cubital vein, labeled, 
processed within one hour after venipuncture, and frozen at −70 degree Celsius. Assays 
were performed in the University of Toledo Laboratory Services blinded to the participants’ 
health and laboratory information. Von Willebrand factor (vWF) antigen (Ag), a well-
established plasma marker of endothelial activation and dysfunction, was analyzed by 
immuno-turbidimetric method, using 0.5 ml of plasma using an automated instrument (STA-
R Evolution® (Diagnostica Stago) (10), with limits of detection being 3%–420%. High 
sensitivity C-reactive protein (hs-CRP) was measured by Near Infrared Particle 
Immunoassay rate methodology using 0.5 ml serum using instrument IMMAGE® 
Immunochemistry Systems (Beckman Coulter) (11), with limits of detection being 0.2 
mg/L- 1440 mg/L. Fibrinogen was analyzed by clot based method using 0.5 ml of plasma 
analyzed by STA-R Evolution® (Diagnostica-Stago) (12), with limits of detection being 60 
mg/dL – 1800 mg/dL. D-dimer is measured by immuno-turbidimetric method using 0.5 ml 
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of Plasma analyzed by STA-R Evolution® (Diagnostica-Stago) (13), with limits of detection 
being 0.27mcg/mL FEU – 20.0 mcg/mL FEU. Factor II activity is measured by mechanical 
clot methodology, an automated method using 0.5 ml plasma analyzed by STA-R 
Evolution® (Diagnostica-Stago) (14), with limits of detection being 2%–1200%.
Statistical Analysis
Based on previous studies of migraine and stroke, and of migraine and biomarkers, the focus 
of our analysis was primarily on the association of biomarker levels with migraine, and its 
subtypes, MA and MO. Initially the relationship was examined at the cohort level, then 
repeated after stratifying by sex. The analysis was extended to explore the biomarker 
association with migraine variables such as headache attack frequency and duration since 
onset of headache. Within the MA cohort, we assessed biomarker association with aura 
frequency and duration since onset of aura. Data were analyzed using the Statistics Package 
for Social Sciences (SPSS) version 21.0. Level of significance was set a priori at p < 0.05 to 
reduce the type I error rate. Descriptive statistics were reported as means and standard 
deviations for continuous and frequencies and percentages for categorical variables. The 
differences in mean vascular biomarker levels between migraine and control groups were 
obtained by computing independent samples t- tests. For a secondary approach, biomarkers 
were divided based on population medians, and values corresponding to greater than or 
lower than the median values, were used to define elevated or lower levels of biomarkers for 
all study participants. Risk of having elevated levels of biomarkers was derived by 
computing the odds ratios with logistic regression analyses. Adjustments for demographic 
and cardiovascular risk factor variables (BMI, smoking, hypertension, cholesterol, use of 
oral contraceptives) were included in the estimation of risk for elevated biomarker levels. 
Odds ratios were computed through logistic regression analysis and used to examine the 
association of elevated biomarkers with migraine and migraine type (MA, MO) compared 
with controls. The adjusted regression model fits were verified using Hosmer Lemeshow 
test. All models except that involved stratified analysis had permissible number of terms not 
exceeding 10% of the sample size of the smaller group in the model. In the migraine cohort 
the relationship between different biomarkers and average headache frequency, average aura 
frequency, total number of years since headache onset and since aura onset was examined 
using multivariate linear regression analyses. For data with deviations from normality, log 
transformation was performed.
Results
The characteristics of the study participants have been previously published (8). In brief, 
patients with migraine with aura and without aura were randomly selected from the GEM 
cases aged 30 to 60 years. The control group was randomly selected from the cohort to 
frequency match the cases by sex, municipality, and age (Table 1). Blood samples for 18 
subjects were not available (due to failed venipuncture in five, insufficient plasma in six, 
hemolysis during initial processing of plasma in one, and damage to sample during transport 
in six), leaving 155 subjects with MA, 128 with MO, and 134 controls. Over 70% of the 
participants were women and the mean age was 48 years. There were no significant 
differences across the groups in education, BMI, hypertension, diabetes mellitus, tobacco 
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use, serum cholesterol, and alcohol consumption. In a comparison of the women in the 
control and migraine groups, there was no difference between the proportions of long 
duration (>15 years) contraceptive use (24.0% v. 24.4%, p=0.94). There were no differences 
between the frequency of migraine in days per year within the MA and MO subtypes.
The biomarkers we selected are related to vascular disease. With the exception of the pairing 
of d-dimer and factor II, there were significant positive correlations between each biomarker 
pairing (data not shown). Adjusting for age, the strongest correlations were between 
fibrinogen and hs-CRP (0.547, p<.001), fibrinogen and factor II (0.356, p<.001), and hs-
CRP and factor II (0.307, p<0.001). In the controls these three correlations, but no others, 
were significant. In the migraine group, and in the MA subgroup, all biomarker correlations 
were significant, except for between D-dimer and each of the following: factor II, vWF Ag, 
and fibrinogen.
In the primary approach, we examined the mean levels of biomarkers between control and 
migraine groups (all migraine, MA and MO) (Table 1). Levels of fibrinogen and hs-CRP 
were elevated in those with migraine as compared to controls, and levels of fibrinogen were 
elevated in the MA subgroup compared to controls. Biomarker levels did not significantly 
differ between MA and MO. Adjustment for age, sex, and level of education did not alter the 
results.
In the secondary approach, we made an unadjusted comparison between control and 
migraine, MA and MO groups based on the proportion of persons with biomarker levels 
above the population median. We demonstrated that compared to controls elevated levels of 
fibrinogen, factor II and hs-CRP were more likely to occur in those with migraine and with 
MA, and elevated levels of fibrinogen in those with MO (Table 2, Model 1). When adjusted 
for factors predictive of some or all of the examined biomarkers (age, sex, BMI, smoking 
status, hypertension, and cholesterol), elevated OR remained for fibrinogen in the migraine 
group and in the MA and MO subgroups and for Factor II in the migraine group and in the 
MA subgroup (Table 2, Model 2). For hs-CRP the association with migraine and with MA 
did not remain significant.
When stratifying by sex, and controlling for age, BMI, smoking status, hypertension, 
cholesterol, and OC use (>15 years), we found in women that elevated levels of fibrinogen 
and factor II were more likely in the migraine group and in the MA subgroup compared to 
controls (Table 3). By contrast, in men vascular biomarkers were not associated with 
migraine and with MA (Table 3).
In the migraine group we assessed the relationship between biomarkers with total years 
since onset and attack frequency for both headache (in MA and MO) and aura (in MA) by 
conducting a multivariate linear regression. Headache and aura frequencies were log 
transformed and age, gender, BMI, and smoking status were included as covariates. Total 
number of years of headache attacks and average number of headache attacks were not 
associated with biomarkers. However, total number of years of aura attacks was a significant 
predictor of hs-CRP (β=0.32, p<0.001). In addition, the average number of aura attacks was 
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a significant predictor of hs-CRP (β=0.39, p<0.001), vWF Ag (β=0.22, p=0.007), D-dimer 
(β=0.26, p=0.001), and fibrinogen (β=0.16, p=0.036).
Discussion
Our results show that in a population-based cohort selected vascular disease biomarkers are 
elevated in migraine, particularly in the subgroups most strongly linked to ischemic stroke 
risk– those with aura, and women. We also demonstrated that within the MA subgroup, it 
was aura, not headache, attack frequency and duration since onset that strengthened the 
association with the biomarkers of fibrinogen, hs-CRP, vWF Ag, and D-dimer.
The major strengths of this study include its population-based design, a standardized 
diagnosis of migraine following ICHD 2 criteria,7 and the detailed description of the cohort 
that allowed us to control for possibly confounding factors due to other cardiovascular 
diseases. All specimens were collected within one year and randomly relative to migraine 
status. Limitations include the fact that the blood samples were analyzed nearly a decade 
after collection. The lower values in this study of the biomarkers fibrinogen and hs-CRP 
compared to some other studies (5,15) indicate that the samples may have lost some of their 
biological activity. It is however unlikely that there was any differential loss between the 
migraine and control samples, leading to false associations. Another limitation is the 
possibility of unaccounted factors influencing the biomarkers, such as the effect of insulin 
and glucose on fibrinogen. Our samples were non-fasting, although with examinations of 
both cases and controls equally distributed over the day, a “fasting” effect in one or the other 
group is unlikely. The small sample size may have resulted in lack of power to detect 
associations between migraine and biomarkers that may potentially exist in larger samples, 
and also to evaluate potential differences in subgroups, such as pre-and postmenopausal 
woman. Given the cross-sectional nature of the study, cause and effect relationships cannot 
be established for the association between migraine, and elevated biomarkers. This study 
also includes exploratory analyses and adjustment of p-values for multiple hypotheses 
testing was not performed and certain findings may be due to chance.
Novel discoveries from this study are the finding that elevated fibrinogen and Factor II levels 
were closely associated with migraine, particularly in women with MA. These associations 
were robust even when controlling for traditional stroke risk factors. Fibrinogen is involved 
in primary hemostasis, platelet aggregation, and leukocyte– endothelial cell interaction, and 
it is the major determinant of whole blood and plasma viscosity (16). Inflammation, from 
any cause, triggers hepatic fibrinogen production. Elevated fibrinogen levels, in turn, induce 
a state of hypercoagulability, cause inflammation and endothelial injury, and aggravate 
cerebral hypoperfusion (17). Fibrinogen may also damage blood vessel walls by causing 
smooth muscle proliferation and migration (18). Thus, elevated fibrinogen may be either the 
cause or consequence of endothelial injury. In some, but not all, epidemiological studies 
fibrinogen has been linked to heart disease and stroke, including in young and middle-aged 
adults (19). Plasma fibrinogen levels have also been associated with the risk of silent 
cerebrovascular lesions (20). A recent systematic review revealed only a few studies of 
fibrinogen in migraine (5). One small study reported an increase of plasma fibrinogen in 
migraineurs compared to controls (21), whereas another small study reported slightly lower 
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plasma levels in persons with migraine (22). The large Women’s Health Study, which 
included women >45 years of age, found no differences in fibrinogen levels between 
migraine and control groups (16).
Coagulation factor II, also known as plasma prothrombin, is a vitamin K– dependent pro-
enzyme that functions in the blood coagulation cascade and is required in the formation of 
fibrin. Increased levels of factor II, as occurs with the inherited prothrombin G20210a 
mutation, has been associated with 2 to 3 fold increased risk for the development of 
thrombosis, but usually in the venous system (23). The mutation has been associated with 
cryptogenic stroke, hypothesized to be related to paradoxical embolism with patent foramen 
ovale (24). Studies of the prothrombin G20210a mutation in migraine revealed no difference 
in the prevalence in persons with migraine compared to controls, including in migraineurs 
who have coexisting ischemic cerebrovascular disease (25). In our study, coagulation factor 
II was associated with migraine, especially migraine with aura, but unlike all the other 
markers, in linear regression analysis factor II was not associated with aura frequency or 
duration since aura onset in the MA subgroup.
We found that hs-CRP, a marker of inflammation and vascular disease, was elevated in 
migraine. The association of hs-CRP with migraine had been previously demonstrated in 
four case-control studies (6,26–28), including one with MO (26) and two with MA (6,27). 
Large population-based studies have also demonstrated that hs-CRP is elevated in persons 
with headache in children and adolescents (29) and in older individuals (15). In the 
population-based Reykjavik Study, however, hs-CRP levels were not increased among 
migraine sufferers compared with non-migraineurs (30). In analysis of the subgroup of 
young adult women (19–34 years), those with MO had borderline higher hs-CRP levels than 
non-migraineurs and those with MA (1.01mg/l vs. 0.81 and 0.75mg/l, p=0.08 and p=0.08).
Plasma levels of vWF antigen, a well-established marker of endothelial activation, correlated 
positively with all the other biomarkers, as well as with aura frequency and duration since 
onset in the MA cohort. Von Willebrand factor antigen levels were not, however, elevated in 
migraine compared to controls. This is in contrast to our clinic-based study where 
premenopausal women with migraine had higher adjusted odds ratios for elevated von 
Willebrand factor activity (OR 6.51; 95% CI, 1.94 to 21.83) (6). There are substantial 
differences in the populations of these two studies, including population type (clinic vs. 
general), proportion of females (100% vs. <75%), mean age (38 years vs. 48 years) and 
headache frequency (12 days per month vs. 1.4 days per month). Further study is needed to 
clarify the reasons for the discrepant results.
Conclusions
This study suggests that endothelial activation, as manifested by elevated biomarkers of 
hypercoagulability and inflammation, is associated with migraine, particularly in women. 
The correlation of biomarker levels with aura frequency and total number of aura-years 
suggests the possibility that aura is causally related to endothelial activation. If true, 
treatments that prevent aura, protect and repair the vasculature, or inhibit platelet 
aggregation and inflammation might prevent stroke in this at-risk subgroup of migraineurs. 
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Whether elevated levels of these biomarkers are associated with subclinical MRI findings or 
with increased prevalence of PFO in this population remains to be determined.
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Clinical implications
• Case-control population-based data in a well-characterized sample 
demonstrate that migraine is associated with biomarkers of hypercoagulability 
and inflammation, two components of endothelial activation.
• The presence of aura, as well as its frequency and years since onset, predict 
vascular biomarker levels, which may contribute to the link between migraine 
with aura and stroke.
• Treatments that prevent aura, protect and repair the vasculature, or decrease 
coagulation and inflammation may prevent stroke in this subgroup of 
migraineurs.
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Table 1
Levels of unadjusted biomarkers for migraine compared to controls and migraine with aura compared to 
migraine without aura
Control
n=134
Migraine
n=283
Migraine with aura
n=155
Migraine without
aura n=128
Age, mean (SE) years 48.18 (0.66) 48.52 (0.46) 48.17 (0.64) 48.95 (0.69)
Females, N (%) 94 (70) 206 (73) 111 (72) 95 (74)
Low Education, N (%) 67 (50) 145 (51) 82 (53) 63 (49)
Body Mass Index, mean (SE) 24.41 (0.32) 25.23 (0.25) 25.56 (0.37) 24.84 (0.35)
Hypertension, N (%) 44 (33) 115 (41) 64 (41) 51 (40)
Diabetes Mellitus, N (%) 5 (4) 4 (1) 1 (0.5) 3 (2.3)
Total Cholesterol, mean (SE), mmol/L 5.23 (0.08) 5.35 (0.05) 5.36 (0.07) 5.34 (0.08)
Smoking  Current, N (%)
      Ever, N (%)
50 (37)
94 (70)
87 (31)
183 (65)
46 (30)
102 (66)
41 (32)
81 (63)
High (≥ 3 units/day) Alcohol Consumption, N (%) 21 (16) 21 (7) 14 (9) 7 (6)
Migraine frequency, mean (SE) days/yr – 16.33(1.05) 15.96(1.54) 16.77(1.39)
Fibrinogen, mean (SE) mg/dL 298.87(5.18) 316.12(3.63)¶ 318(4.95) ¶ 313.70(5.34)
D-dimer, mean (SE) mcg/mL FEU 0.35(0.02) 0.32(0.01) 0.33(0.02) 0.32(0.01)
Factor II activity, mean (SE) % lab norm 108.14(1.23) 110.21(0.96) 111.07(1.29) 109.17(1.45)
vWF antigen, mean (SE) % lab norm 109.51(1.97) 109.69(2.32) 106.55(3.05) 113.48(3.54)
hs-CRP, mean (SE) mg/L 2.56(0.28) 3.43(0.27) ¶ 3.52(0.38) 3.30(0.39)
Values reported in the table are means ± standard error (SE) of biomarker levels. vWF: von Willebrand factor, hs-CRP: high sensitivity C-reactive 
protein. Blood samples available for 134 controls and 283 migraineurs (Migraine with aura [MA]=155 and Migraine without aura [MO]=128)
¶
= migraine vs. controls, p <0.05. Fibrinogen: Migraine vs. control, p=0.007, MA vs. control, p=0.02; hs-CRP: Migraine vs. control, p=0.03 
Adjustment for age, gender, and education did not alter the comparison results between MA, MO, and controls.
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